Lantern Pharma Inc is a biotechnology company focused on leveraging artificial intelligence and machine learning to accelerate the drug discovery and development process, particularly for oncology therapeutics
The company aims to identify and develop personalized treatment options that target specific patient populations based on their genetic profiles and responses to various therapies. By harnessing advanced technologies, Lantern Pharma seeks to streamline clinical trials and bring innovative cancer treatments to market more efficiently, ultimately improving patient outcomes and advancing the field of precision medicine.
All but one of the 7 artificial intelligence stock categories that I analyze weekly increased in value this week. But two categories are still down MTD, suggesting that the surge in the artificial intelligence technology sector is slowing.
The AI-powered drug discovery market is projected to grow at a 30% CAGR between now and 2030, with annual sales in excess of $50 billion anticipated. An AI drug discovery revolution is underway.
With the promise of lower costs and shorter development timelines, AI-enabled drug discovery holds massive potential to increase the accessibility of drugs and to treat presently incurable conditions.
